Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial
Year: 2025
Type: article
Language: en
Topic: HER2/EGFR in Cancer Research
Authors and affiliations:
raw_author_name: David Planchard
raw_affiliation_strings: Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France; Faculty of Medicine, Paris-Saclay University, Paris, France. Electronic address: David.PLANCHARD@gustaveroussy.fr
raw_author_name: Hye Ryun Kim
raw_affiliation_strings: Division of Medical Oncology, Yonsei Cancer Center, Seoul, Republic of Korea
raw_author_name: Thatthan Suksombooncharoen
raw_affiliation_strings: Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
raw_author_name: Rubi Li
raw_affiliation_strings: Section of Medical Oncology, St Luke's Medical Center, Metro Manila, Philippines
raw_author_name: Diego Cortinovis
raw_affiliation_strings: Division of Medical Oncology, Fondazione IRCCS San Gerardo dei Tintori Monza, Monza, Italy; Department of Medicine, University of Milano-Bicocca, Milan, Italy
raw_author_name: Ji-Youn Han
raw_affiliation_strings: Center for Lung Cancer, National Cancer Center, Goyang-si Gyeonggi-do, Republic of Korea
raw_author_name: Jens Samol
raw_affiliation_strings: Department of Medical Oncology, Tan Tock Seng Hospital, Singapore; Johns Hopkins University, Baltimore, Maryland; Lee Kong Chian School of Medicine/Nanyang Technological University, Singapore
raw_author_name: Yotsawaj Runglodvatana
raw_affiliation_strings: Department of Medicine, Faculty of Medicine Vajira Hospital, Bangkok, Thailand
raw_author_name: Kang-Yun Lee
raw_affiliation_strings: Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan
raw_author_name: Gee-Chen Chang
raw_affiliation_strings: School of Medicine, Chung Shan Medical University, Taichung City, Taiwan; Institute of Medicine, Chung Shan Medical University, Taichung City, Taiwan; Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung City, Taiwan
raw_author_name: Chun-Hui Lee
raw_affiliation_strings: Department of Oncology, National Cheng Kung University Hospital, Tainan, Taiwan
raw_author_name: Dariusz Kowalski
raw_affiliation_strings: Department of Lung and Chest Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
raw_author_name: Stephanie P.L. Saw
raw_affiliation_strings: Division of Medical Oncology, National Cancer Center Singapore, Singapore; Duke-National University of Singapore Medical School, Singapore
raw_author_name: Yiqing Huang
raw_affiliation_strings: Department of Hematology-Oncology, National University Cancer Institute, Singapore
raw_author_name: Gerrina Ruiter
raw_affiliation_strings: Department of Clinical Pharmacology and Thoracic Oncology, The Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands
raw_author_name: Myung-Ju Ahn
raw_affiliation_strings: Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea
raw_author_name: Tsung-Ying Yang
raw_affiliation_strings: Department of Chest Medicine, Taichung Veterans General Hospital, Taichung City, Taiwan; Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung City, Taiwan
raw_author_name: Cheng-Ta Yang
raw_affiliation_strings: Chang Gung Memorial Hospital, Taoyuan, Taiwan
raw_author_name: Aumkhae Sookprasert
raw_affiliation_strings: Medical Oncology Unit, Department of Medicine, Faculty of Medicine, Khon Kaen University, Muang District, Thailand
raw_author_name: Erica C. Nakajima
raw_affiliation_strings: Clinical Development, Late-Stage Development, Oncology R&D, AstraZeneca, Gaithersburg, Maryland
raw_author_name: Jose Alfon
raw_affiliation_strings: Clinical Development, Late-Stage Development, Oncology R&D, AstraZeneca, Barcelona, Spain
raw_author_name: Robert McEwen
raw_affiliation_strings: Oncology Data Science, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
raw_author_name: Yi-Ting Chang
raw_affiliation_strings: Oncology Biometrics, Late-Stage Development, Oncology R&D, AstraZeneca, Gaithersburg, Maryland
raw_author_name: James CH. Yang
raw_affiliation_strings: Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei City, Taiwan